Open Nav

Please submit your session questions in advance at

Immunic AG

  • Daniel Vitt, Immunic AG

Immunic is a specialist in selective oral drugs in immunology and focused on developing novel oral therapies with best-in-class potential for chronic inflammatory and autoimmune diseases. The company’s three development programs target inflammatory bowel diseases, multiple sclerosis, and psoriasis and include orally available, small molecule inhibitors of DHODH (IMU-838 program), an inverse agonist of RORγt (IMU-935 program), and IMU-856 (undisclosed novel target). Immunic’s lead development program, IMU-838, an orally available, small molecule inhibitor of DHODH, is currently in phase 2 clinical development for ulcerative colitis, with additional phase 2 trials in Crohn’s disease, multiple sclerosis, and primary sclerosing cholangitis planned for 2019. The company was founded in 2016 withheadquarters in Planegg-Martinsried, Germany. Immunic is privately held and supported by several renowned healthcare investors.

  • Date:Monday, February 11
  • Time:9:45 AM - 10:00 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23347
  • Goal for Presentation:Presentation of company to possible new investors and BD contacts, networking and exchange
  • Company Website:
  • Company HQ City:82152 Planegg-Martinsried
  • Company HQ Country:Germany
  • Total Amount Raised to Date, in All Rounds:EUR 31.7 million (USD 37.5 million)
  • Previous and Current Investors:LSP, Omega Funds, Fund+, LifeCare Partners, High-Tech Gründerfonds, Bayern Kapital, IBG
  • CEO/Top Company Official:Dr. Daniel Vitt
  • Year Founded:2016
  • Main Therapeutic Focus:Immunology
  • Lead Product in Development:IMU-838, small molecule inhibitors of DHODH
  • Development Phase of Primary Product:Phase II
Daniel Vitt
Immunic AG